Does Ozempic Help Type 1 Diabetes? Insights into New Research and Weight Management

Q: What compounded GLP-1 options does PlexusDx offer for Type 1 patients?

PlexusDx offers compounded Semaglutide Injection ($179–$229/mo), Oral Semaglutide ($249/mo), Tirzepatide Injection ($229–$309/mo), and Microdose GLP-1 Protocol ($129/mo)—all from licensed 503A compounding pharmacies. All require a valid healthcare provider prescription and close medical oversight for Type 1 use.

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists, including compounded formulations, are being studied for Type 1 diabetes management—primarily for weight management and cardiovascular benefit rather than insulin replacement. Clinical trials show modest HbA1c improvements when combined with insulin, though individual responses vary considerably based on metabolic and genetic factors.

Type 1 diabetes patients considering GLP-1 therapy face unique clinical questions: Who benefits most? What baseline biomarkers predict response? How do genetic factors in peptide signaling pathways influence outcome likelihood? PlexusDx supports precision-wellness by helping you understand your individual context before starting therapy, enabling more informed conversations with your care team.

GLP-1 Therapy in Type 1 Diabetes: Current Clinical Evidence

Recent research indicates GLP-1 agonists may reduce HbA1c by 0.3–0.5% in Type 1 patients when combined with intensive insulin therapy. The primary benefit is weight management—many patients experience 2–4 kg reductions—and cardiovascular protection, not glycemic control alone. Type 1 diabetes requires baseline insulin; GLP-1 is an adjunctive therapy.

Studies including the ADJUNCT ONE and ADJUNCT TWO trials showed GLP-1 therapy reduced insulin dose requirements without worsening glycemic control. However, response heterogeneity is significant: some patients see meaningful benefit, others minimal change. This variability underscores the importance of understanding your individual metabolic and genetic profile before initiating therapy.

Biomarkers and Genetic Factors That May Inform GLP-1 Candidacy

Before starting GLP-1 therapy, several biomarkers and genetic variants may help contextualize your likely response profile. These include GLP-1 receptor sensitivity, insulin secretion capacity, and variants in peptide signaling pathways. Your provider should evaluate fasting glucose, C-peptide, lipid profile, and kidney function as baseline safety markers.

Biomarker / Genetic Factor	Clinical Significance for Type 1 GLP-1 Consideration
GLP1R rs6923761 variant	Influences GLP-1 receptor function; may affect baseline GLP-1 responsiveness and weight loss trajectory.
Fasting C-peptide level	Reflects residual beta cell function; higher C-peptide may associate with better glycemic response in early-stage Type 1.
Lipid profile (LDL, HDL, triglycerides)	Establishes baseline cardiovascular risk; GLP-1 therapy offers secondary benefit here independent of weight loss.
Kidney function (eGFR)	Essential safety marker; some GLP-1 formulations require dose adjustment or caution below eGFR 30 mL/min/1.73m².

Who Is a Candidate for GLP-1 Therapy in Type 1 Diabetes?

Type 1 patients most likely to benefit from GLP-1 therapy typically have overweight or obesity, suboptimal cardiovascular risk profile, or difficulty managing weight on insulin alone. Ideal candidates maintain relatively stable baseline glycemic control and have no contraindications (active pancreatitis, severe gastroparesis, personal/family history of medullary thyroid cancer).

Your provider should assess insulin sensitivity, current insulin requirements, and metabolic flexibility before starting. Patients with brittle diabetes, severe hypoglycemia unawareness, or very early-stage Type 1 (within first 1–2 years of diagnosis) may need individualized risk-benefit evaluation. Pregnancy or plans to conceive require special consideration.

Safety Considerations and Provider-Guided Decision-Making

GLP-1 therapy in Type 1 diabetes requires careful insulin dose titration—hypoglycemia risk increases if insulin is not adjusted concurrently. Gastrointestinal side effects, including nausea and delayed gastric emptying, may worsen in patients with existing gastroparesis. Rare but serious risks include pancreatitis; baseline pancreatic history must be reviewed.

Starting GLP-1 therapy should always occur under medical supervision with clear plans for insulin adjustment, follow-up labs, and symptom monitoring. Your provider may recommend starting with lower doses (e.g., microdose protocols) to assess tolerability. Regular HbA1c checks, kidney function monitoring, and cardiovascular assessments are standard practice during therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test reveals predispositions in key peptide signaling pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that may help provide context for how your body's metabolic machinery responds to GLP-1 therapy. These genetic variants do not determine your outcome, but they may support a more nuanced conversation with your provider about candidacy and baseline expectations.

In Type 1 diabetes specifically, understanding your GLP-1 receptor sensitivity and weight-regulation genetics (FTO, MC4R variants) may inform whether you're more likely to experience meaningful weight loss and metabolic improvement on GLP-1 therapy. The test predicts genetic predispositions in peptide pathways, not exact medication response or glycemic control—these still depend on insulin management, lifestyle, and individual physiology.

Pairing your genetic insights with clinical biomarkers (C-peptide, kidney function, lipid profile) and comprehensive provider evaluation creates a stronger foundation for personalized decision-making. Whether you pursue compounded GLP-1 options or other therapies, understanding your underlying peptide pathway predispositions can support more confident, informed conversations with your healthcare team about what approach aligns with your Type 1 diabetes management goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is GLP-1 therapy FDA-approved for Type 1 diabetes?

No GLP-1 is currently FDA-approved specifically for Type 1 diabetes. Semaglutide and other GLP-1 agonists are approved for Type 2 diabetes and weight management. Use in Type 1 is considered off-label and must be prescribed and monitored by a qualified healthcare provider based on individual clinical judgment.

How much weight do Type 1 patients typically lose on GLP-1 therapy?

Clinical trials show Type 1 patients average 2–4 kg weight loss when combining GLP-1 with insulin therapy over 6–12 months. Individual results vary significantly based on baseline metabolism, insulin dose adjustments, diet, and genetic factors—some patients see greater reductions, others minimal change.

What compounded GLP-1 options does PlexusDx offer for Type 1 patients?

PlexusDx offers compounded Semaglutide Injection ($149/mo), Oral Semaglutide ($249/mo), Tirzepatide Injection ($249/mo), and Microdose GLP-1 Protocol ($129/mo)—all from licensed 503A compounding pharmacies. All require a valid healthcare provider prescription and close medical oversight for Type 1 use.

What is the main risk of GLP-1 in Type 1 diabetes?

The primary risk is hypoglycemia if insulin doses are not adjusted appropriately when starting GLP-1. GLP-1 slows gastric emptying and reduces appetite, lowering insulin requirements. Your provider must actively titrate insulin downward and monitor blood glucose closely to prevent dangerously low readings.

Can the Precision Peptide Genetic Test predict if I'll respond well to GLP-1?

The Precision Peptide Genetic Test reveals predispositions in GLP-1 and weight-regulation pathways (GLP1R, FTO, MC4R variants) that may provide context for baseline responsiveness. It does not predict exact medication response—clinical biomarkers, insulin management, and provider oversight remain essential for determining real-world outcomes.